Exceptional long term response to crizotinib in ROS 1‐postive advanced non small cell lung cancer

Abstract Non‐small‐cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Her...

Full description

Bibliographic Details

Published in:	Respirology Case Reports
Main Authors:	Anjali Murali, Anju Farsana A, Sobha Subramaniam, Malini Eapen, Indu R. Nair, Keechilat Pavithran
Format:	Article
Language:	English
Published:	Wiley 2024-09-01
Subjects:	actionable genomic alterations crizotinib non‐small‐cell lung cancer prolonged PFS ROS1 rearrangement
Online Access:	https://doi.org/10.1002/rcr2.70033